Test Price
2,800 AED✅ Home Collection Available
BCL9L Gene Heterotaxy, Visceral, BCL9L Related Genetic Test DHA-Approved
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary Post-Test Telephonic Clinical Guidance for result interpretation with a DHA-licensed specialist.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The BCL9L Gene Heterotaxy, Visceral NGS Test is a next-generation sequencing analysis designed to detect pathogenic variants in the BCL9L gene, the primary genetic cause of visceral heterotaxy and congenital laterality defects. This comprehensive genetic test enables early diagnosis and family planning through precise mutation identification.
| Feature | BCL9L NGS Test (Our Test) | Standard Heterotaxy Gene Panel |
|---|---|---|
| Diagnostic Sensitivity | 99.9% (ISO 9001:2015 verified) | ~95% (limited gene coverage) |
| Methodology | Advanced NGS (Next-Generation Sequencing) | NGS panel or Sanger sequencing |
| Turnaround Time | 3 to 4 Weeks | 5 to 6 Weeks |
| Pre-Test Genetic Counselling | Included (pedigree chart & clinical history) | Often not included |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that the BCL9L gene test is a powerful diagnostic tool for heterotaxy, but results must always be interpreted alongside clinical and imaging findings. Genetic counseling before and after testing is essential for understanding implications and guiding management.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory & Medication Warning
This genetic test provides important information, but it should never be used as a sole reason to alter or discontinue prescribed medications. Always consult your treating physician before making any changes to your treatment plan.
Safety & Exclusion Criteria
- Exclusion Criteria: Patients unable to provide a viable blood sample or with active systemic infections that may compromise sample integrity.
- Emergency Red Flags: If you or your child develop sudden severe shortness of breath, cyanosis (bluish skin), or crushing chest pain after specimen collection or during the waiting period, seek immediate emergency medical attention. These could indicate undiagnosed complex congenital heart disease associated with heterotaxy.
Patient FAQ & Clinical Guidance
1. What is the BCL9L gene test and who should consider it?
Answer: This genetic test identifies BCL9L gene mutations linked to left-right body axis malformations, enabling early clinical intervention for heterotaxy syndrome. It is indicated for neonates, children, or adults with congenital heart defects, situs inversus, or a family history of visceral laterality disorders. A comprehensive genetic counselling session is required before testing.
2. How accurate is this test and why does it take 3–4 weeks?
Answer: Our BCL9L NGS boasts 99.9% diagnostic sensitivity through ISO-certified deep sequencing, minimizing false-negative and false-positive results. The 3–4-week turnaround includes DNA extraction, library preparation, sequencing on high-throughput platforms, bioinformatic variant calling, and a double-blinded clinical interpretation by two independent geneticists, ensuring the highest reliability.
3. How is the sample collected and what does the home collection service include?
Answer: A DHA-certified phlebotomist collects a small blood sample (or dried blood spot on FTA card) in your home using a cold-chain transport kit. The service operates daily from 8 AM to 11 PM, includes sample tracking, and complies with ISO 9001:2015 cold-chain protocols to preserve DNA integrity until it reaches our accredited genomics laboratory.
UAE Regulatory & Data Privacy Adherence
This test fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genomic data is encrypted and processed in our ISO 9001:2015 accredited facility (DNA Labs UAE, DHA Facility License Number: 1143). Patient consent and safety are governed under Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Parameter | Details |
|---|---|
| Test Name | BCL9L Gene Heterotaxy, Visceral, BCL9L Related Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Q20.3 (Heterotaxy syndrome) |
| LOINC Code | 104143-7 (BCL9L gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License 1143, DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians